BD named Vitor Roque as chief financial officer Thursday, ending the medtech company’s seven-month search for a permanent ...

Indian American business leader aims to build a world-class delivery and performance platform at leading medical technology ...

Q2 fiscal 2026 Management view "We delivered a solid second quarter with revenue, adjusted margins and adjusted EPS all ahead of our expectations" (President, CEO & Chairman Thomas Polen), adding, ...

BD (NYSE:BDX) today announced the appointment of a new CFO alongside Street-beating second-quarter financial results.

Travis Steed, the medical device analyst at Bank of America. Next up, we have Becton, Dickinson, Tom Polen, CEO; and Vitor Roque, the newly announced CFO. I think you've been to Vegas a couple of ...

Medical technology company Becton, Dickinson and Company (NYSE:BDX) announced in Q1 CY2026, with sales up 5.2% year on year ...

Marietta, Ga.-based Wellstar Health System is partnering with medtech company Becton Dickinson and Company (BD) to integrate ...

After parting ways with its diabetes franchise nearly three years ago, BD is slimming down even further with a plan to divest its diagnostic and biosciences businesses as the company nears the finish ...

On February 5, 2025, Becton, Dickinson and Company (BD) announced plans to separate its Biosciences and Diagnostic Solutions business into an independent entity. The Biosciences and Diagnostic ...